PatientsVille.com Logo

BLOOD CHOLESTEROL INCREASED and Metformin

PatientsVille

BLOOD CHOLESTEROL INCREASED Symptoms and Causes

What is an inactive lifestyle?

Being a couch potato. Not exercising. A sedentary or inactive lifestyle. You have probably heard of all of these phrases, and they mean the same thing: a lifestyle with a lot of sitting and lying down, with very little to no exercise.

In the United States and around the world, people are spending more and more time doing sedentary activities. During our leisure time, we are often sitting: while using a computer or other device, watching TV, or playing video games. Many of our jobs have become more sedentary, with long days sitting at a desk. And the way most of us get around involves sitting - in cars, on buses, and on trains.

How does an inactive lifestyle affect your body?

When you have an inactive lifestyle,

  • You burn fewer calories. This makes you more likely to gain weight.
  • You may lose muscle strength and endurance, because you are not using your muscles as much
  • Your bones may get weaker and lose some mineral content
  • Your metabolism may be affected, and your body may have more trouble breaking down fats and sugars
  • Your immune system may not work as well
  • You may have poorer blood circulation
  • Your body may have more inflammation
  • You may develop a hormonal imbalance
What are the health risks of an inactive lifestyle?

Having an inactive lifestyle can be one of the causes of many chronic diseases. By not getting regular exercise, you raise your risk of

  • Obesity
  • Heart diseases, including coronary artery disease and heart attack
  • High blood pressure
  • High cholesterol
  • Stroke
  • Metabolic syndrome
  • Type 2 diabetes
  • Certain cancers, including colon, breast, and uterine cancers
  • Osteoporosis and falls
  • Increased feelings of depression and anxiety

Having a sedentary lifestyle can also raise your risk of premature death. And the more sedentary you are, the higher your health risks are.

How can I get started with exercise?

If you have been inactive, you may need to start slowly. You can keep adding more exercise gradually. The more you can do, the better. But try not to feel overwhelmed, and do what you can. Getting some exercise is always better than getting none. Eventually, your goal can be to get the recommended amount of exercise for your age and health.

There are many different ways to get exercise; it is important to find the types that are best for you. You can also try to add activity to your life in smaller ways, such as at home and at work.

How can I be more active around the house?

There are some ways you can be active around your house:

  • Housework, gardening, and yard work are all physical work. To increase the intensity, you could try doing them at a more vigorous pace.
  • Keep moving while you watch TV. Lift hand weights, do some gentle yoga stretches, or pedal an exercise bike. Instead of using the TV remote, get up and change the channels yourself.
  • Work out at home with a workout video (on your TV or on the internet)
  • Go for a walk in your neighborhood. It can be more fun if you walk your dog, walk your kids to school, or walk with a friend.
  • Stand up when talking on the phone
  • Get some exercise equipment for your home. Treadmills and elliptical trainers are great, but not everyone has the money or space for one. Less expensive equipment such as yoga balls, exercise mats, stretch bands, and hand weights can help you get a workout at home too.
How can I be more active at work?

Most of us sit when we are working, often in front of a computer. In fact, less than 20 percent of Americans have physically active jobs. It can be challenging to fit physical activity into your busy workday, but here are some tips to help you get moving:

  • Get up from your chair and move around at least once an hour
  • Stand when you are talking on the phone
  • Find out whether your company can get you a stand-up or treadmill desk
  • Take the stairs instead of the elevator
  • Use your break or part of your lunch hour to walk around the building
  • Stand up and walk to a colleague's office instead of sending an email
  • Have "walking" or standing meetings with co-workers instead of sitting in a conference room

Check out the latest treatments for BLOOD CHOLESTEROL INCREASED

BLOOD CHOLESTEROL INCREASED treatment research studies

Metformin clinical trials, surveys and public health registries


Find Drug Side Effect reports



Metformin Side Effects

Lactic Acidosis (2533)
Renal Failure Acute (1526)
Diarrhoea (990)
Vomiting (735)
Blood Glucose Increased (635)
Hypotension (588)
Nausea (587)
Haemodialysis (566)
Hypoglycaemia (554)
Completed Suicide (515)
Metabolic Acidosis (488)
Abdominal Pain (385)
Dehydration (375)
Renal Failure (366)
Cardiac Arrest (346)
Dyspnoea (333)
Malaise (311)
Toxicity To Various Agents (287)
Hyperkalaemia (276)
Dizziness (259)
Overdose (258)
Renal Impairment (256)
Blood Creatinine Increased (235)
Asthenia (233)
Intentional Overdose (229)
Suicide Attempt (227)
Confusional State (213)
Fatigue (212)
Myocardial Infarction (207)
Weight Decreased (196)
Decreased Appetite (183)
Hypothermia (179)
Headache (177)
Abdominal Pain Upper (177)
Pancreatitis Acute (175)
Blood Glucose Decreased (163)
Pain (161)
Shock (159)
Continuous Haemodiafiltration (157)
Multi-organ Failure (153)
Abdominal Discomfort (153)
Somnolence (149)
Fall (149)
Agitation (148)
Diabetes Mellitus Inadequate Control (145)
Loss Of Consciousness (143)
Pancreatitis (137)
Pneumonia (126)
Poisoning (125)
Hypertension (120)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

At what age should stop taking this drug?

Been on metformin for 4 days so far for Pcos and have eaten it with food and i am having sever diahrea and cramps. i have to take 500mg once a day for 2 weeks and then 2 times a day for 2 weeks and then 3 times a day and i dunno how to make

Bleeding gums

By using the medicine for 3 months,there was symptoms of impotency.

Coma causing motor cycle accident. brain damage. family difficulties not being able to work causing financial problems

Ever since I started taking Metformin almost a year now, I have had a cough and it will not go away.

Fatigue severe pain down left arm dizziness shortness of breath palputations and shere lack of get up and go

Feeling nervous

Feeling sleepy, fatigue, and tiredall the time. My vision is also gone seriously blurred.

Got up this morning and I was covered with a rash much like poisen ivy, and very itchy. Also my eyes were almost swelled shut. and the bag part under my eyes was full of fluid. Quit the Med formin immedietly and seem bet

I've been taking Coversyl for almost two weeks now. My doctor prescribed it when the Natrilix I had been taking for a couple of months wasn't bringing my blood pressure down fast enough. The only side effects I've noticed since commencing the C

Does panadeine increase blood pressure?

I HAD 1 SHOT OF THIS AND WITHIN 12 HOURS I WENT FROM A VERY NORMAL BLOOD PRESSURE TO WAKING AT 5 A.M. NEXT DAY WITH 198/110 AND 104 PULSE RATE. IT HAS CONTINUED ALL WEEK AFTER AND I'M NOW ON A BLOOD PRESSURE DRUG TO TRY AND CONTROL IT. EVEN WITH DR

I have been put on Molipaxin 3 weeks ago, I have dry mouth, hair loss and my panic attacks were showing no signs of improvement. Dr increased it to 100mg and put me onto Lamictin. I am not bi polar nor epileptic. My disorder ist algora phoebia. I a

I have just come back from a funeral for my brother. He was just 62. He was on statin medicine but his cholestrol, blood pressure, weight and diet was very much in control. In fact just a day before his death the doctor told him that he was doing f

Side effects I have from Nadolol are confusion, dizziness, lightheaded, increased depression and anxiety, and mild nausea.

Since taking Karvezide (2years after Karvea was proved to unsuccessfull in reducing my high blood pressusre) I have experienced a lot of problems with nasal drip and a permanent muscas build up in the throat. Nothing seems to relieve the problem.

When I reported to my doctor that i was frequently having to urinate he had a blood test carried out with the result that my prostrate was OK he prescribed Permixon 160 mg twice per day and Tamsulosina STADA 0,4 mg once per day. I am now urinating

Have taken hydrea for a year because my spleen had increased in size. I have noticed increased loss of memory and some confusion for the past couple of months. I take 500 mg every other day and 1000 mg every other day.

fell dizziness and was admitted. Doc execute with dianostic including blood teat and heart check all. good. Doc make a decision by saying i'm getting Vertigo and treat with BETASERC. Below is the effect after 2 days take this medicine:- I was

BLOOD CHOLESTEROL INCREASED Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Influence of the Use of the Diabetic Drug Metformin on the Overall Survival and Treatment-related Toxicity in Advanced Stage Non-small Cell Lung Cancer Patients.
Condition: Non Small Cell Lung Cancer
Intervention:
Outcome Measures: Assessment of Metformin use;   Assessment of insulin use;   Overall assessment of overall survival and toxicity factors
2 Recruiting Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Metformin IR;   Drug: Saxagliptin;   Drug: Saxagliptin/Metformin XR FDC;   Drug: Metformin XR
Outcome Measures: Maximum observed plasma concentration (Cmax) of Saxagliptin;   Area under the plasma concentration-time curve from time zero to 24 hours [AUC(0-24)] of Saxagliptin;   Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of Saxagliptin;   Maximum observed plasma concentration (Cmax) of 5-hydroxy Saxagliptin;   Area under the plasma concentration-time curve from time zero to 24 hours [AUC(0-24)] of 5-hydroxy Saxagliptin;   Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of 5-hydroxy Saxagliptin;   Maximum observed plasma concentration (Cmax) of Metformin;   Area under the plasma concentration-time curve from time zero to 24 hours [AUC(0-24)] of Metformin;   Area under the plasma concentration-time curve from time zero to 12 hours [AUC(0-12)] of Metformin;   Safety: based on medical review of adverse event reports and the results of vital sign measurements, ECGs, physical examinations, and clinical laboratory tests;   Formulation swallowability of Saxagliptin-Metformin FDC tablet, Glucophage® IR tablet and Glucophage® XR tablet
3 Not yet recruiting Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Low Metformin;   Drug: Metformin;   Drug: Mid Metformin;   Drug: High Metformin
Outcome Measures: Change In Fasting Plasma Glucose;   Gastrointestinal Effects;   Change in Baseline-Corrected Plasma Glucose and Insulin Area Under The Concentration Curves;   Change in Insulin Secretory Rates;   Change in Fasting Plasma Lipids;   Change in HbA1c;   Change in HOMA-IR;   Change In 7-Point Glucose Profiles;   Change In Serial Blood Glucose Concentrations;   Safety and Tolerability
4 Unknown  Reducing Antipsychotic-Induced Weight Gain in Children With Metformin
Conditions: Obesity;   Weight Gain;   Psychotropic Induced Weight Gain
Intervention: Drug: Metformin
Outcome Measures: Change in weight;   Weight trajectory based on length of intervention and factors that predict response to Metformin
5 Recruiting PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
Conditions: Diabetes Mellitus, Non-Insulin-Dependent;   Hypertriglyceridemia
Interventions: Drug: Metformin Eicosapentaenoate;   Drug: Metformin HCl and Vascepa
Outcome Measure: AUC following single and repeat single oral administration of Metformin eicosapentaenoate, Metformin hydrochloride and Vascepa
6 Recruiting Study of Metformin With Simvastatin for Men With Prostate Carcinoma
Condition: Prostate Carcinoma
Interventions: Drug: Metformin;   Drug: Simvastatin
Outcome Measures: Efficacy, as measured by an improvement in PSA doubling time (PSADT) between baseline and 6 months, of the combination of Metformin plus simvastatin in patients with recurrent prostate cancer following definitive treatment.;   Time to protocol-specified event for men treated with the combination of Metformin plus simvastatin.;   Pattern of change in log PSA levels and PSA velocity over time during treatment with Metformin plus simvastatin.;   Associations between changes in metabolic parameters (fasting glucose/insulin/lipid panel/leptin/adiponectin and others) with the pattern of change in log PSA levels.
7 Recruiting Efficacy and Safety of Alogliptin and Metformin Fixed-dose Combination in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus
Interventions: Drug: Alogliptin;   Drug: Metformin HCl;   Drug: Alogliptin and Metformin fixed-dose combination (FDC);   Drug: Alogliptin placebo;   Drug: Metformin placebo;   Drug: Alogliptin and Metformin FDC placebo
Outcome Measures: Change From Baseline to Week 26 (or Early Termination) in Glycosylated Hemoglobin (HbA1c);   Change From Baseline in HbA1c Over Time;   Change From Baseline in Fasting Plasma Glucose Over Time;   Time to hyperglycemic rescue event;   Percentage of Participants Meeting Rescue Criteria;   Percentage of Participants With Marked Hyperglycemia;   Change From Baseline in Body Weight Over Time;   Percentage of Participants With Glycosylated Hemoglobin ≤ 6.5%;   Percentage of Participants With Glycosylated Hemoglobin ≤ 7.0%;   Percentage of Participants With Glycosylated Hemoglobin ≤ 7.5%;   Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 0.5%;   Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1.0%;   Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1.5%;   Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 2.0%
8 Recruiting Bioequivalence of a Medium, Fixed Dose Combination Tablet of Linagliptin/Metformin Extended Release in Healthy Subjects.
Condition: Healthy
Interventions: Drug: Linagliptin;   Drug: Metformin;   Drug: Linagliptin/Metformin FDC
Outcome Measures: Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours (AUC0-72);   Maximum measured concentration of linagliptin in plasma (Cmax);   Area under the concentration-time curve of Metformin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz);   Cmax of Metformin in plasma;   Area under the concentration-time curve of linagliptin and Metformin in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf);   AUC0-inf of Metformin in plasma
9 Recruiting Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Metformin XR;   Drug: Metformin IR;   Drug: Placebo matching with Metformin XR;   Drug: Placebo matching with Metformin IR
Outcome Measures: Mean change in glycosylated hemoglobin (HbA1c) from baseline to Week 24;   Mean change in fasting plasma glucose (FPG) from baseline to Week 24;   Mean change in Mean Daily Glucose (MDG) from baseline to Week 24;   Percent of subjects with HbA1c <7%
10 Recruiting Targeting Pathways in Polycystic Ovary Syndrome (PCOS) Using Metformin (MET)
Condition: Polycystic Ovary Syndrome
Intervention: Drug: Metformin
Outcome Measures: Change in Insulin Sensitivity (SI) after 3 Months of Metformin Therapy;   Change in Peripheral Flow-Mediated Vasodilatation after 3 Months of Metformin Therapy
11 Recruiting A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer
Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: Metformin alone (Arm A);   Drug: Metformin (Arm B);   Drug: rapamycin (Arm B)
Outcome Measure: safety and feasibility
12 Recruiting Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis
Conditions: Polycystic Ovary Syndrome;   Disorder of Glucose Regulation
Interventions: Drug: Metformin XR;   Drug: Saxagliptin;   Drug: Saxagliptin-Metformin XR
Outcome Measures: Fasting and 2 hour glucose levels after glucose load;   ß-cell compensatory function;   Surrogate measures of insulin sensitivity and secretion;   Cardiometabolic risk factors;   Free androgen index
13 Recruiting Bioequivalence of a Low, Fixed Dose Combination Tablet of Linagliptin/Metformin Extended Release in Healthy Subjects
Condition: Healthy
Interventions: Drug: Linagliptin;   Drug: Linagliptin/Metformin ER FDC;   Drug: Metformin ER
Outcome Measures: Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours (AUC0-72);   Maximum measured concentration of linagliptin in plasma (Cmax);   Area under the concentration-time curve of Metformin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz);   Cmax of Metformin in plasma;   Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf);   AUC0-inf of Metformin in plasma
14 Recruiting Bioequivalence of a High, Fixed Dose Combination Tablet of Linagliptin/Metformin Extended Release in Healthy Subjects
Condition: Healthy
Interventions: Drug: Linagliptin/Metformin ER FDC;   Drug: Linagliptin;   Drug: Metformin ER
Outcome Measures: Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours (AUC0-72);   Maximum measured concentration of linagliptin in plasma (Cmax);   Area under the concentration-time curve of Metformin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz);   Cmax of Metformin in plasma;   Area under the concentration-time curve of Metformin in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf);   AUC0-inf of linagliptin in plasma
15 Recruiting Relative Bioavailability of Multiple Oral Doses of BI 187004 and Metformin After Co-administration Compared to Multiple Oral Doses of BI 187004 Alone and Metformin Alone in Healthy Male Subjects
Condition: Healthy
Interventions: Drug: Metformin;   Drug: BI 187004
Outcome Measures: AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t) for BI 187004;   AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t) for Metformin;   Cmax,ss (Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t) for BI 187004;   Cmax,ss (Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t) for Metformin
16 Recruiting Metformin for the Treatment of Endometrial Hyperplasia
Conditions: Endometrial Hyperplasia;   Endometrial Hyperplasia Without Atypia
Intervention: Drug: Metformin
Outcome Measures: Response Rate;   Toxicity evaluation;   Patient Compliance;   Potential molecular markers in response to treatment with Metformin
17 Not yet recruiting A Study With or Without Metformin to Determine if Metformin Can Prevent Weight Gain and Other Problems (i.e. Diabetes, Increased Cholesterol, Etc.) That Can Arise From the Use of Hormonal Therapy in Combination With Radiation Therapy When Treating Aggressive Localized Prostate Cancer.
Condition: Prostatic Neoplasm
Interventions: Drug: Metformin;   Drug: Placebo
Outcome Measures: Mean body weight at 12 months of follow-up;   Prevalence and incidence of Metabolic Syndrome
18 Recruiting Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk
Condition: Breast Cancer Prevention
Interventions: Drug: Metformin;   Drug: Placebo
Outcome Measures: change from baseline in breast density at 6 and 12 months;   change from baseline in serum insulin levels at 6 and 12 months;   change from baseline in serum IGF-1 to IGFBP-3 ratio at 6 and 12 months;   change from baseline in serum testosterone levels at 6 and 12 months;   change from baseline in serum leptin to adiponectin ratio at 6 and 12 months;   change from baseline in body weight at 6 and 12 months;   change from baseline in waist circumference at 6 and 12 months;   change from baseline in serum IGF-2 levels at 6 and 12 months
19 Not yet recruiting The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study
Conditions: Diabetes Mellitus, Type 2;   Diabetes
Interventions: Drug: Metformin;   Drug: Detemir;   Drug: Liraglutide;   Drug: Insulin Aspart
Outcome Measures: Composite end-point;   Mean change from randomization in A1c at week 26;   Percentage of patients reaching target A1c of <7% at week 26;   Percentage of patients reaching pre-specified "treatment failure" outcome;   Mean change from randomization in body weight;   Percentage of patients who lost 5% or more of body weight from randomization;   Hypoglycemic episodes;   Percentage of patients experiencing any hypoglycemic episode;   Diabetes Quality of Life (DQOL)questionnaire score;   Short Form-36 (SF-36) questionnaire score;   Number of daily injections;   Health care cost, total;   Health care cost, diabetes-related;   Number of titration events by healthcare professional;   Number of titration events by patient;   Healthcare provider time during scheduled office (minutes/visit);   Healthcare provider time, unscheduled (total minutes);   Compliance with pharmacologic therapy;   Change in LDL cholesterol from baseline to week 26;   Change in triglycerides from baseline;   7-point glucose profiles over 2 consecutive days
20 Recruiting Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer
Condition: Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions: Drug: Metformin;   Drug: Placebo
Outcome Measures: Clinical response rate;   Pathologic complete response rate;   Changes of Ki67(%);   Breast conservation rate;   Breast density change;   Toxicity profile of letrozole and Metformin